Market Cap: $30.46B
AI
Alnylam Pharmaceuticals, Inc.
ALNY
NASDAQ (NASDAQ Global Select)USD
Market Cap: $30.46B
Alnylam Pharmaceuticals (Ticker: ALNY) strategically enhances its capabilities through an expanded collaboration with Komodo Health. This partnership, which utilizes Komodo's Marmot analytics AI platf…
Alnylam Pharmaceuticals (Ticker: ALNY) forges a groundbreaking partnership with Inceptive Nucleics that aims to revolutionize RNA interference drug discovery through the integration of generative AI t…
Alnylam Pharmaceuticals (Ticker: ALNY) forges a groundbreaking partnership with Inceptive Nucleics valued up to $2 billion, aiming to transform drug discovery through artificial intelligence. This col…
Alnylam Pharmaceuticals (Ticker: ALNY), a leader in RNA interference (RNAi) therapeutics, forges a transformative collaboration with Inceptive Nucleics that could reshape its research landscape. This…
Alnylam Pharmaceuticals (Ticker: ALNY) transforms its Board of Directors by expanding from ten to eleven members, reflecting its commitment to strengthening governance as it navigates challenges in it…
Alnylam Pharmaceuticals: Pioneering RNAi Therapeutics in a Volatile Market Landscape Amidst the recent volatility in financial markets, Alnylam Pharmaceuticals continues to innovate within the biophar…
Alnylam Pharmaceuticals: Pioneering Treatments for Rare Genetic Conditions Alnylam Pharmaceuticals is carving a significant niche in the biotech sector with its innovative approach to addressing rare…
Alnylam Pharmaceuticals: Leading the Charge in Rare Disease Treatment Alnylam Pharmaceuticals stands at the forefront of biopharmaceutical innovation, particularly in the realm of rare genetic disorde…
Alnylam Pharmaceuticals Fuels Innovation in Cardiac Disease Therapy through Strategic Collaboration with Tenaya Therapeutics Alnylam Pharmaceuticals Inc. enters into a noteworthy collaboration with Te…
Alnylam Pharmaceuticals Partners with Helix to Advance RNAi Therapeutics through Enhanced Genomic Insights Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, enters into a tran…
Transformative Collaboration: Alnylam Pharmaceuticals Partners with Helix for Genomic Advancements Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapeutics, announces a significant mu…
Navigating Market Sentiment: Alnylam Pharmaceuticals in a Competitive Landscape Alnylam Pharmaceuticals stands at a pivotal juncture as it continues to develop innovative therapies within the biotechn…
Alnylam Pharmaceuticals: Insider Transaction Signals Confidence in RNAi Therapeutics Alnylam Pharmaceuticals, a leader in the biopharmaceutical sector specializing in RNA interference (RNAi) therapeut…
Alnylam Pharmaceuticals: Insider Confidence in RNAi Therapeutics Alnylam Pharmaceuticals continues to assert its position as a leading innovator in the biopharmaceutical sector, particularly in the fi…
Alnylam Pharmaceuticals: Pioneering RNAi Therapeutics for Rare Diseases Alnylam Pharmaceuticals, a leader in the development of RNA interference (RNAi) therapeutics, continues to make strides in trans…
Regeneron Board Member's Stock Option Exercise Signals Confidence in Biopharmaceutical Innovations In a recent filing with the Securities and Exchange Commission (SEC), Regeneron Pharmaceuticals’ Boar…
Regeneron’s Leadership Moves Signal Confidence in Biotechnology Sector Recent developments within Regeneron Pharmaceuticals highlight the pivotal role of executive actions in shaping perceptions withi…
Alnylam Pharmaceuticals: Advancing RNAi Therapeutics Amid Industry Challenges Alnylam Pharmaceuticals stands at the forefront of an innovative wave in the biotechnology sector, focusing on RNA interfe…
Alnylam Pharmaceuticals Demonstrates Executive Confidence Through Stock Option Exercise In a recent development, Alnylam Pharmaceuticals’ CEO, Greenstreet, exercises stock options in a significant tra…
Alnylam Pharmaceuticals Advances RNA Interference Therapeutics Alnylam Pharmaceuticals, a leader in RNA interference (RNAi) therapies, continues to position itself as a key player in the biopharmaceut…
Title: Novo Nordisk's Coramitug Trial Advances Understanding of Transthyretin Amyloidosis with Cardiomyopathy Recent developments in the treatment of transthyretin amyloidosis with cardiomyopathy (ATT…
Alnylam Pharmaceuticals Faces Increased Short Interest Amid Market Uncertainties Alnylam Pharmaceuticals Inc., a leader in RNA interference (RNAi) therapeutics, currently experiences a notable rise in…
Alnylam Pharmaceuticals Navigates Market Challenges Amid Earnings Miss Alnylam Pharmaceuticals Inc. faces a challenging period after reporting a mixed performance in its third-quarter earnings. The co…
Alnylam Pharmaceuticals Champions Innovation in RNAi Therapeutics Amid Industry Developments Alnylam Pharmaceuticals stands at the forefront of the biopharmaceutical industry, focusing on the developm…
### Alnylam Pharmaceuticals: Advancing RNA Interference Therapies Amid Strong Demand Alnylam Pharmaceuticals is poised to release its quarterly earnings on October 30, 2025, and anticipation is high a…